Anebulo Pharmaceuticals Analyst Ratings
Anebulo Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | 154.78% | Benchmark | → $8 | Reiterates | Speculative Buy → Speculative Buy |
| 09/25/2023 | 91.08% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 09/21/2023 | 91.08% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 09/18/2023 | 91.08% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 05/18/2023 | 154.78% | Benchmark | → $8 | Reiterates | Speculative Buy → Speculative Buy |
| 02/14/2023 | 154.78% | Benchmark | $10 → $8 | Maintains | Speculative Buy |
| 07/27/2022 | 91.08% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 05/25/2021 | 377.71% | Benchmark | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/03/2023 | 154.78% | 基準 | →$8 | 重申 | 投機性買入→投機性買入 |
| 09/25/2023 | 91.08% | HC Wainwright公司 | →$6 | 重申 | 購買→購買 |
| 2023年09月21日 | 91.08% | Maxim集團 | →$6 | 開始承保 | →購買 |
| 09/18/2023 | 91.08% | HC Wainwright公司 | →$6 | 開始承保 | →購買 |
| 2023年05月18日 | 154.78% | 基準 | →$8 | 重申 | 投機性買入→投機性買入 |
| 02/14/2023 | 154.78% | 基準 | $10→$8 | 維護 | 投機性購買 |
| 07/27/2022 | 91.08% | 拉登堡·塔爾曼 | →$6 | 開始承保 | →購買 |
| 2021/05/25 | 377.71% | 基準 | →$15 | 開始承保 | →購買 |
What is the target price for Anebulo Pharmaceuticals (ANEB)?
AneBulo製藥公司(ANEB)的目標價是多少？
The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by Benchmark on October 3, 2023. The analyst firm set a price target for $8.00 expecting ANEB to rise to within 12 months (a possible 154.78% upside). 6 analyst firms have reported ratings in the last year.
安妮寶製藥(納斯達克：ANEB)的最新目標價是由Benchmark於2023年10月3日報道的。這家分析公司將目標價定為8美元，預計ANEB將在12個月內上漲至(可能上漲154.78%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Anebulo Pharmaceuticals (ANEB)?
分析師對安妮寶製藥(ANEB)的最新評級是多少？
The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ: ANEB) was provided by Benchmark, and Anebulo Pharmaceuticals reiterated their speculative buy rating.
納斯達克(Sequoia Capital：ANEB)的最新分析師評級由Benchmark提供，AneBulo PharmPharmticals重申其投機性買入評級。
When is the next analyst rating going to be posted or updated for Anebulo Pharmaceuticals (ANEB)?
AneBulo PharmPharmticals(ANEB)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與AneBulo製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。AneBulo製藥的上一次評級是在2023年10月3日提交的，所以你應該預計下一次評級將在2024年10月3日左右的某個時候公佈。
Is the Analyst Rating Anebulo Pharmaceuticals (ANEB) correct?
分析師對AneBulo製藥公司(ANEB)的評級正確嗎？
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a reiterated with a price target of $0.00 to $8.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $3.14, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的AneBulo製藥(ANEB)評級被重申，目標價在0.00美元至8.00美元之間。AneBulo PharmPharmticals(ANEB)目前的交易價格為3.14美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。